-
2 weeks ago | 
targetedonc.com | Benjamin P. Saylor
The combination of zanzalintinib and nivolumab (Opdivo) has demonstrated encouraging effectiveness and acceptable tolerability in individuals with previously untreated stage 4 renal cell carcinoma (RCC).
-
2 weeks ago | 
targetedonc.com | Benjamin P. Saylor
Subgroup analyses from the phase 3 CREST trial (NCT04165317) revealed that combining sasanlimab with BCG enhanced event-free survival (EFS). This benefit was observed in patients with high-risk non–muscle invasive bladder cancer (NMIBC), specifically those with carcinoma in situ (CIS) and T1 tumors, when compared to BCG alone.1The findings were presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, by Thomas B.
-
2 weeks ago | 
targetedonc.com | Benjamin P. Saylor
Interim data from the phase 3 ENLIGHTED trial (NCT04620239) indicates that padeliporfin vascular targeted photodynamic (VTP) therapy is both safe and effective for treating low-grade upper tract urothelial cancer. “This treatment is efficacious, at least in this interim analysis. It does have an excellent safety profile. Recruitment will continue and hopefully will result in approval,” said presenting author Vitaly Margulis, MD, the Paul C.
-
3 weeks ago | 
onclive.com | Benjamin P. Saylor
Padeliporfin vascular targeted photodynamic (VTP) therapy generated antitumor activity, including a complete response rate of 73%, and low-grade toxicity in patients with low-grade upper tract urothelial cancer, according to data from an interim analysis of the phase 3 ENLIGHTED trial (NCT04620239) presented during the 2025 ASCO Annual Meeting. "This treatment is efficacious, at least in this interim analysis. It does have an excellent safety profile.
-
3 weeks ago | 
urologytimes.com | Benjamin P. Saylor
The combination of zanzalintinib and nivolumab (Opdivo) showed promising efficacy and manageable safety in previously untreated stage 4 renal cell carcinoma (RCC), with a 63% response rate and 18.5-month median progression-free survival (PFS) reported in an expansion cohort of the STELLAR-002 study (NCT05176483).1“Zanzalintinib with nivolumab demonstrated promising clinical activity and tolerability in patient with first-line stage 4 RCC.
-
3 weeks ago | 
urologytimes.com | Benjamin P. Saylor
A large, retrospective study of nearly 200,000 patients with prostate cancer from the Epic Cosmos database revealed a rise in the use of GLP-1 and GIP/GLP-1 receptor agonists over the past decade, with usage patterns influenced by age and socioeconomic vulnerability.1The findings were presented in a poster at the 2025 American Society of Clinical Oncology Annual Meeting in Chicago, Illinois.
-
3 weeks ago | 
urologytimes.com | Benjamin P. Saylor
In the phase 3 ARANOTE trial (NCT04736199), darolutamide (Nubeqa) plus androgen deprivation therapy (ADT) significantly delayed deterioration of health-related quality of life (HRQoL) compared with placebo in patients with metastatic hormone-sensitive prostate cancer (mHSPC), with notable improvements in pain and several HRQoL subscales.1“Darolutamide confers a positive impact on health-related quality of life, as assessed within this study.
-
3 weeks ago | 
urologytimes.com | Benjamin P. Saylor
In the phase 2 COMRADE trial (NCT03317392), reduced-dose olaparib (Lynparza) combined with radium-223 (Ra-223, Xofigo) significantly improved radiographic progression-free survival (rPFS) over Ra-223 alone in patients with metastatic castration-resistant prostate cancer (mCRPC) and bone metastases, particularly among those without prior docetaxel and with limited bone involvement.1 “Reduced-dose olaparib plus radium-223 resulted in significant improvements in radiographic progression-free...
-
3 weeks ago | 
urologytimes.com | Benjamin P. Saylor
Darolutamide (Nubeqa) demonstrated modest antitumor activity in molecularly defined subgroups of patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with androgen receptor pathway inhibitors (ARPIs), according to findings from the phase 2 CCTG IND.234: PC_BETS trial presented at the 2025 American Society of Clinical Oncology Annual Meeting in Chicago, Illinois.1 “Darolutamide is structurally distinct from other AR antagonists (enzalutamide [Xtandi],...
-
3 weeks ago | 
urologytimes.com | Benjamin P. Saylor
ARASTEP, a phase 3 randomized, double-blind, placebo-controlled study (NCT05794906) that is actively recruiting, is set to evaluate the use of darolutamide (Nubeqa) plus androgen deprivation therapy (ADT) for the treatment of high-risk biochemical recurrence of prostate cancer.1 In a presentation at the 2025 American Society of Clinical Oncology Annual Meeting in Chicago, Illinois, Alicia Morgans, MD, MPH, a genitourinary medical oncologist and the director of the Survivorship Program at...
